Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia

被引：0
作者：
Claviez, A
Eckert, C
Seegel, K
Schrauder, A
Schrappe, M
Henze, G
von Stackelberg, A
机构：
[1] Univ Med Ctr Schleswig, Dept Pediat, D-24105 Kiel, Germany
[2] Charite Med Ctr, Dept Pediat Hematol & Oncol, Berlin, Germany
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2006年 / 91卷 / 02期
关键词：
B-cell precursor ALL; rituximab; CD20; antigen; children;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We treated three children with relapsed or refractory CD20 positive B-cell precursor acute lymphoblastic leukemia with rituximab in combination with chemotherapy, which produced a decreasing or persistent low positive minimal residual disease load. Two children subsequently underwent allogeneic stem cell transplantation and remain in complete remission at days +399 and +332.
引用
收藏
页码：272 / 273
页数：2
相关论文
共 9 条
[1]   Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL [J].
Bader, P ;
Hancock, J ;
Kreyenberg, H ;
Goulden, NJ ;
Niethammer, D ;
Oakhill, A ;
Steward, CG ;
Handgretinger, R ;
Beck, JF ;
Klingebiel, T .
LEUKEMIA, 2002, 16 (09) :1668-1672
[2]  
BENE MC, 1995, LEUKEMIA, V9, P1783
[3]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[4]   Induction of long-term remission of a relapsed childhood B-Acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation [J].
Corbacioglu, S ;
Eber, S ;
Gungor, T ;
Hummerjohann, J ;
Niggli, F .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (04) :327-329
[5]   Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma [J].
de Vries, MJ ;
Veerman, AJP ;
Zwaan, CM .
BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (03) :414-415
[6]   Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia [J].
Eckert, C ;
Biondi, A ;
Seeger, K ;
Cazzaniga, G ;
Hartmann, R ;
Beyermann, B ;
Pogodda, M ;
Proba, J ;
Henze, G .
LANCET, 2001, 358 (9289) :1239-1241
[7]   Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy:: Results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Miinster Group 87 [J].
Einsiedel, HG ;
von Stackelberg, A ;
Hartmann, R ;
Fengler, R ;
Schrappe, M ;
Janka-Schaub, G ;
Mann, G ;
Hählen, K ;
Göbel, U ;
Klingebiel, T ;
Ludwig, WD ;
Henze, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7942-7950
[8]  
HENZE G, 2003, CONTEMPORARY CLIN NE, P199
[9]   Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) [J].
Mounier, N ;
Briere, J ;
Gisselbrecht, C ;
Emile, JF ;
Lederlin, P ;
Sebban, C ;
Berger, F ;
Bosly, A ;
Morel, P ;
Tilly, H ;
Bouabdallah, R ;
Reyes, F ;
Gaulard, P ;
Coiffier, B .
BLOOD, 2003, 101 (11) :4279-4284
1